Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

Its revenue increased by "only" 20% year over year to $11.4 billion. Eli Lilly's newest medicines for diabetes and obesity, ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

A special event is aimed at answering questions and giving local residents the best information about those medications.

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...

Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) work by ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...